Expression profile of tyrosine kinases in breast cancer

被引:0
|
作者
Meric, F
Lee, WP
Sahin, A
Zhang, HX
Kung, HJ
Hung, MC
机构
[1] Univ Texas, MD Anderson Canc Ctr, Dept Mol & Cellular Oncol, Houston, TX 77030 USA
[2] Univ Texas, MD Anderson Canc Ctr, Dept Surg Oncol, Houston, TX 77030 USA
[3] Univ Texas, MD Anderson Canc Ctr, Dept Pathol, Houston, TX 77030 USA
[4] Univ Calif Davis, Ctr Canc, Dept Biol Chem, Sacramento, CA 95817 USA
关键词
D O I
暂无
中图分类号
R73 [肿瘤学];
学科分类号
100214 ;
摘要
The tyrosine kinase (TK) family includes many growth factor receptors, cell cycle regulators, and oncoproteins. Moreover, the receptor TKs HER2/neu and epidermal growth factor receptor are overexpressed in a subgroup of breast tumors and correlate with more aggressive behavior. Thus, TKs are being actively pursued as therapeutic targets. The purpose of this study was to determine the expression pattern of TKs in breast cancer. Reverse transcription-PCR was performed with degenerate primers based on conserved motifs of the catalytic domains of TKs, and the identities of the reverse transcription-PCR products were determined by digestion with a panel of restriction enzymes. Using a TK display assay, we studied the TK profiles of 13 breast cancer cell lines and two normal immortalized breast epithelial cell lines. The TK display assay reproducibly demonstrated known differences in HER-2/neu expression between cell lines. Several TKs, including receptor TKs Axl, Cak, fibroblast growth factor receptor 4, HEK8, HER2/neu, c-MET, RET, and nonreceptor TKs ARG, BRK, Janus kinase 1, Rak, and YES were detected in breast cancer cells. Several kinases were differentially expressed among the cell lines. Similar TK profiles were found using RNA from human breast tumors. We conclude that there is significant variability in the TK expression pattern of breast cancers. This variability should be considered when selecting TK inhibitors to treat patients.
引用
收藏
页码:361 / 367
页数:7
相关论文
共 50 条
  • [21] Expression Profile of Inflammatory Breast Cancer
    M. Yu. Shkurnikov
    I. N. Nechaev
    N. A. Khaustova
    N. A. Krainova
    N. A. Savelov
    V. N. Grinevich
    E. K. Saribekyan
    Bulletin of Experimental Biology and Medicine, 2013, 155 : 667 - 672
  • [22] Expression Profile of Inflammatory Breast Cancer
    Shkurnikov, M. Yu.
    Nechaev, I. N.
    Khaustova, N. A.
    Krainova, N. A.
    Savelov, N. A.
    Grinevich, V. N.
    Saribekyan, E. K.
    BULLETIN OF EXPERIMENTAL BIOLOGY AND MEDICINE, 2013, 155 (05) : 667 - 672
  • [24] Activation of Abl tyrosine kinases promotes invasion of aggressive breast cancer cells
    Srinivasan, Divyamani
    Plattner, Rina
    CANCER RESEARCH, 2006, 66 (11) : 5648 - 5655
  • [25] ROLE OF EGF RECEPTOR TYROSINE KINASES IN BREAST CANCER. A BIOPHYSICAL APPROACH
    Szollosi, J.
    Vereb, G.
    Barok, M.
    Palyi-Krekk, Z.
    Nagy, P.
    CYTOMETRY PART B-CLINICAL CYTOMETRY, 2008, 74B (06) : 385 - 385
  • [26] Targeting receptor tyrosine kinases in HER2-negative breast cancer
    Anandappa, Gayathri
    Turner, Nicholas C.
    CURRENT OPINION IN ONCOLOGY, 2013, 25 (06) : 594 - 601
  • [27] Review Article Receptor tyrosine kinases in breast cancer treatment: unraveling the potential
    Qi, Yu
    Deng, Shu-Min
    Wang, Kuan-Song
    AMERICAN JOURNAL OF CANCER RESEARCH, 2024, 14 (09): : 4172 - 4196
  • [28] Programmed Death-Ligand 1 and Receptor Tyrosine Kinases in Breast Cancer
    Ayoub, Nehad
    Al-Diabat, Muhsen
    Al-Shorman, Moath
    Al-Eitan, Laith
    CANCER RESEARCH, 2024, 84 (09)
  • [29] Receptor tyrosine kinases (RTKs) in breast cancer: signaling, therapeutic implications and challenges
    Butti, Ramesh
    Das, Sumit
    Gunasekaran, Vinoth Prasanna
    Yadav, Amit Singh
    Kumar, Dhiraj
    Kundu, Gopal C.
    MOLECULAR CANCER, 2018, 17
  • [30] Receptor tyrosine kinases (RTKs) in breast cancer: signaling, therapeutic implications and challenges
    Ramesh Butti
    Sumit Das
    Vinoth Prasanna Gunasekaran
    Amit Singh Yadav
    Dhiraj Kumar
    Gopal C. Kundu
    Molecular Cancer, 17